Industry Newsbiotechiovanceearningsinvestor relations
Iovance Surges After UBS Raises Target
4.1
Iovance Biotherapeutics shares jumped 32.9% week-on-week after UBS doubled its price target to $4 from $2 while keeping a neutral rating, ahead of the company's participation at Barclays' 28th Annual Global Healthcare Conference on March 11. The firm reported a 5% wider full-year net loss of $390.98 million versus $372 million in 2024, with total revenues rising 60.6% to $263.5 million; Q4 net loss narrowed to $71.9 million and Q4 revenue increased to $86.7 million.
Key Points
- 1Shares jumped 32.9% after UBS doubled its price target to $4 from $2
- 2UBS maintained a neutral stance, signaling cautious optimism before March 11 Barclays conference
- 3Financials show revenue growth but widening annual net loss, affecting valuation and investor risk assessment
Scoring Rationale
Credible company filings and analyst update justify interest, but limited novelty and narrow single-company scope.
Sources
Public references used for this report.
Practice with real FinTech & Trading data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Verified Users by Income TierEasyTechnology Stocks with High BetaMediumPortfolio Performance ScorecardHard
250 free problems · No credit card
See all FinTech & Trading problems